Pharmaco-economic Inequalities in Access to Antifibrotic Treatment for Interstitial Lung Disease in the Asia-Pacific Region.

ABSTRACT: Antifibrotic drugs, available for the best part of the last decade in many parts of the world, have improved outcomes in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. However, it is unclear whether patients suffering from these devastating conditions have timely and adequate access to antifibrotic therapy in the Asia-Pacific region (APAC). In this mixed-methods narrative review of 12 APAC countries, integration of questionnaire-based insights of 31 regional clinical experts in interstitial lung disease (ILD) with publicly available pharmaco-economic information has been used to understand how country-specific challenges impact on antifibrotic accessibility. Overall, a broad range of approaches are utilized to provide antifibrotic treatment including centra

SUBMITTER: Chua F 

PROVIDER: S-EPMC12488351 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature